miR-185 acts as a tumor suppressor by targeting AKT1 in non-small cell lung cancer cells

International Journal of Clinical and Experimental Pathology

Volumn 8, Issue 9, 2015, Pages 11854-11862

  Li, Shuai ^a   Ma, Yulian ^a   Hou, Xinfang ^a   Liu, Ying ^a   Li, Ke ^a   Xu, Shuning ^a   Wang, Jufeng ^a  

^a ZHENGZHOU UNIVERSITY   (China)

Author keywords

AKT1; MiR 185; Non small cell lung cancer

Indexed keywords

AKT1 PROTEIN, HUMAN; MICRORNA; MIRN185 MICRORNA, HUMAN; PROTEIN KINASE B;

ANIMAL; BAGG ALBINO MOUSE; CELL MOTION; CELL PROLIFERATION; ENZYMOLOGY; FEMALE; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; HUMAN; LUNG TUMOR; METABOLISM; NON SMALL CELL LUNG CANCER; NUDE MOUSE; PATHOLOGY; SIGNAL TRANSDUCTION; TIME FACTOR; TUMOR CELL LINE; TUMOR INVASION; TUMOR VOLUME;

ANIMALS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; NEOPLASM INVASIVENESS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; TUMOR BURDEN;

EID: 85013339889     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Jemal A, Siegel R, Xu J and Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60: 277-300.
2. Anglim PP, Alonzo TA and Laird-Offringa IA. DNA methylation-based biomarkers for early detection of non-small cell lung cancer: an update. Mol Cancer 2008; 7: 81.
3. Verdecchia A, Francisci S, Brenner H, Gatta G, Micheli A, Mangone L and Kunkler I. Recent cancer survival in Europe: a 2000-02 period analysis of EUROCARE-4 data. Lancet Oncol 2007; 8: 784-796.
4. Lan D, Zhang X, He R, Tang R, Li P, He Q and Chen G. MiR-133a is downregulated in non-small cell lung cancer: a study of clinical significance. Eur J Med Res 2015; 20: 50.
5. Pan B, Chen Y, Song H, Xu Y, Wang R and Chen L. Mir-24-3p downregulation contributes to VP16-DDP resistance in small-cell lung cancer by targeting ATG4A. Oncotarget 2015; 6: 317-331.
6. Huang H, Jiang Y, Wang Y, Chen T, Yang L, He H, Lin Z, Liu T, Yang T, Kamp DW, Wu B and Liu G. miR-5100 promotes tumor growth in lung cancer by targeting Rab6. Cancer Lett 2015; 362: 15-24.
7. Wang LJ, He CC, Sui X, Cai MJ, Zhou CY, Ma JL, Wu L, Wang H, Han SX and Zhu Q. MiR-21 promotes intrahepatic cholangiocarcinoma proliferation and growth in vitro and in vivo by targeting PTPN14 and PTEN. Oncotarget 2015; 6: 5932-5946.
8. Liang HL, Hu AP, Li SL, Xie JP, Ma QZ and Liu JY. MiR-454 Prompts Cell Proliferation of Human Colorectal Cancer Cells by Repressing CYLD Expression. Asian Pac J Cancer Prev 2015; 16: 2397-2402.
9. Jiang J, Zhang Y, Guo Y, Yu C, Chen M, Li Z, Tian S and Sun C. MicroRNA-3127 promotes cell proliferation and tumorigenicity in hepato-cellular carcinoma by disrupting of PI3K/AKT negative regulation. Oncotarget 2015; 6: 6359-6372.
10. Yao Q, Cao Z, Tu C, Zhao Y, Liu H and Zhang S. MicroRNA-146a acts as a metastasis suppre-ssor in gastric cancer by targeting WASF2. Cancer Lett 2013; 335: 219-224.
11. Chen P, Wang BL, Pan BS and Guo W. MiR-1297 regulates the growth, migration and invasion of colorectal cancer cells by targeting cyclo-oxygenase-2. Asian Pac J Cancer Prev 2014; 15: 9185-9190.
12. Yang T, Thakur A, Chen T, Yang L, Lei G, Liang Y, Zhang S, Ren H and Chen M. MicroRNA-15a induces cell apoptosis and inhibits metastasis by targeting BCL2L2 in non-small cell lung cancer. Tumour Biol 2015; 36: 4357-4365.
13. Esquela-Kerscher A and Slack FJ. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 2006; 6: 259-269.
14. Zhang XF, Li KK, Gao L, Li SZ, Chen K, Zhang JB, Wang D, Tu RF, Zhang JX, Tao KX, Wang G and Zhang XD. miR-191 promotes tumorigenesis of human colorectal cancer through targeting C/EBPbeta. Oncotarget 2015; 6: 4144-4158.
15. He D, Wang J, Zhang C, Shan B, Deng X, Li B, Zhou Y, Chen W, Hong J, Gao Y, Chen Z and Duan C. Down-regulation of miR-675-5p contributes to tumor progression and development by targeting pro-tumorigenic GPR55 in non-small cell lung cancer. Mol Cancer 2015; 14: 73.
16. Li Q, Wang JX, He YQ, Feng C, Zhang XJ, Sheng JQ and Li PF. MicroRNA-185 regulates chemotherapeutic sensitivity in gastric cancer by targeting apoptosis repressor with caspase recruitment domain. Cell Death Dis 2014; 5: e1197.
17. Wang R, Tian S, Wang HB, Chu DP, Cao JL, Xia HF and Ma X. MiR-185 is involved in human breast carcinogenesis by targeting Vegfa. FEBS Lett 2014; 588: 4438-4447.
18. Tang H, Wang Z, Liu X, Liu Q, Xu G, Li G and Wu M. LRRC4 inhibits glioma cell growth and invasion through a miR-185-dependent pathway. Curr Cancer Drug Targets 2012; 12: 1032-1042.
19. Ma X, Shen D, Li H, Zhang Y, Lv X, Huang Q, Gao Y, Li X, Gu L, Xiu S, Bao X, Duan J and Zhang X. MicroRNA-185 inhibits cell proliferation and induces cell apoptosis by targeting VEGFA directly in von Hippel-Lindau-inactivated clear cell renal cell carcinoma. Urol Oncol 2015; 33: 169. e1-11.
20. Qadir XV, Han C, Lu D, Zhang J and Wu T. miR-185 inhibits hepatocellular carcinoma growth by targeting the DNMT1/PTEN/Akt pathway. Am J Pathol 2014; 184: 2355-2364.
21. Zhang N, Wang X, Huo Q, Sun M, Cai C, Liu Z, Hu G and Yang Q. MicroRNA-30a suppresses breast tumor growth and metastasis by targeting metadherin. Oncogene 2014; 33: 3119-3128.
22. Zhu S, Deng S, Ma Q, Zhang T, Jia C, Zhuo D, Yang F, Wei J, Wang L, Dykxhoorn DM, Hare JM, Goldschmidt-Clermont PJ and Dong C. MicroRNA-10A* and MicroRNA-21 modulate endothelial progenitor cell senescence via suppressing high-mobility group A2. Circ Res 2013; 112: 152-164.
23. Dong R, Liu X, Zhang Q, Jiang Z, Li Y, Wei Y, Yang Q, Liu J, Wei JJ, Shao C, Liu Z and Kong B. miR-145 inhibits tumor growth and metas-tasis by targeting metadherin in high-grade serous ovarian carcinoma. Oncotarget 2014; 5: 10816-10829.
24. Xiang Y, Ma N, Wang D, Zhang Y, Zhou J, Wu G, Zhao R, Huang H, Wang X, Qiao Y, Li F, Han D, Wang L, Zhang G and Gao X. MiR-152 and miR-185 co-contribute to ovarian cancer cells cisplatin sensitivity by targeting DNMT1 directly: a novel epigenetic therapy independent of decitabine. Oncogene 2014; 33: 378-386.
25. Tang H, Liu P, Yang L, Xie X, Ye F, Wu M, Liu X, Chen B and Zhang L. miR-185 suppresses tumor proliferation by directly targeting E2F6 and DNMT1 and indirectly upregulating BRCA1 in triple-negative breast cancer. Mol Cancer Ther 2014; 13: 3185-3197.
26. Takahashi Y, Forrest AR, Maeno E, Hashimoto T, Daub CO and Yasuda J. MiR-107 and MiR-185 can induce cell cycle arrest in human non small cell lung cancer cell lines. PLoS One 2009; 4: e6677.
27. Linnerth-Petrik NM, Santry LA, Petrik JJ and Wootton SK. Opposing functions of Akt isoforms in lung tumor initiation and progression. PLoS One 2014; 9: e94595.
28. Testa JR and Tsichlis PN. AKT signaling in normal and malignant cells. Oncogene 2005; 24: 7391-7393.
29. Shen G, Rong X, Zhao J, Yang X, Li H, Jiang H, Zhou Q, Ji T, Huang S, Zhang J and Jia H. MicroRNA-105 suppresses cell proliferation and inhibits PI3K/AKT signaling in human hepatocellular carcinoma. Carcinogenesis 2014; 35: 2748-2755.
30. Sun M, Wang G, Paciga JE, Feldman RI, Yuan ZQ, Ma XL, Shelley SA, Jove R, Tsichlis PN, Nicosia SV and Cheng JQ. AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Am J Pathol 2001; 159: 431-437.